Application and challenge of immunotherapy in perioperative therapy of gastric cancer

Chi XUE; Peng GAO; Zhi ZHU; Zhenning WANG

doi:10.19401/j.cnki.1007-3639.2024.03.003

您当前的位置：

首页 >

文章列表页 >

Application and challenge of immunotherapy in perioperative therapy of gastric cancer

Specialist' Commentary | 更新时间：2025-12-31

- Application and challenge of immunotherapy in perioperative therapy of gastric cancer
- China Oncology Vol. 34, Issue 3, Pages: 259-267(2024)
- 作者机构：
  
  中国医科大学附属第一医院胃肠肿瘤外科，辽宁沈阳 110001
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.03.003
  CLC： R735.2
- Received：27 February 2024，
  
  Revised：2024-03-13，
  
  Published：30 March 2024
- 稿件说明：
移动端阅览
Chi XUE, Peng GAO, Zhi ZHU, et al. Application and challenge of immunotherapy in perioperative therapy of gastric cancer[J]. China Oncology, 2024, 34(3): 259-267.
DOI：

Chi XUE, Peng GAO, Zhi ZHU, et al. Application and challenge of immunotherapy in perioperative therapy of gastric cancer[J]. China Oncology, 2024, 34(3): 259-267. DOI： 10.19401/j.cnki.1007-3639.2024.03.003.

摘要

胃癌是中国常见的消化系统恶性肿瘤之一，进展期及晚期患者占比高，围手术期治疗方案的选择始终是临床上的难点。对多数局部进展期胃癌，围手术期治疗模式相较于标准根治术联合术后辅助化疗的模式，也许可以进一步改善患者生存，但传统化疗方案的疗效已达到平台期，传统分子靶向治疗进展相对缓慢，近年来，随着免疫治疗在晚期胃癌治疗中的地位不断提升，越来越多的临床研究表明，免疫治疗在围手术期胃癌患者中也可以取得较好的疗效。本文就近年来免疫治疗在胃癌围手术期中应用的研究进展进行述评。

Abstract

Gastric cancer is one of the common malignant tumors of digestive system in our country. The proportion of patients in advanced and late stage is large

and the choice of perioperative treatment program is always difficult in clinic. For most locally advanced gastric cancer

compared with standard radical surgery combined with postoperative adjuvant chemotherapy

perioperative treatment mode may further improve the survival of patients. However

the efficacy of conventional chemotherapy regimen has reached a plateau

while the progress of traditional molecular targeted therapy is relatively slow. In recent years

with the increasing role of immunotherapy in the treatment of advanced gastric cancer

more and more clinical studies have shown that immunotherapy can also achieve better efficacy in perioperative gastric cancer patients. This article reviewed the research progress of immunotherapy in perioperative gastric cancer in recent years.

关键词

Keywords

references

KANG Y K , BOKU N , SATOH T , et al . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet , 2017 , 390 ( 10111 ): 2461 - 2471 . DOI: 10.1016/S0140-6736(17)31827-5 http://doi.org/10.1016/S0140-6736(17)31827-5 https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275 https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275

JANJIGIAN Y Y , BENDELL J , CALVO E , et al . CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer [J ] . J Clin Oncol , 2018 , 36 ( 28 ): 2836 - 2844 . DOI: 10.1200/JCO.2017.76.6212 http://doi.org/10.1200/JCO.2017.76.6212

SHITARA K , AJANI J A , MOEHLER M , et al . Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer [J ] . Nature , 2022 , 603 ( 7903 ): 942 - 948 . DOI: 10.1038/s41586-022-04508-4 http://doi.org/10.1038/s41586-022-04508-4

KANG Y K , CHEN L T , RYU M H , et al . Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2022 , 23 ( 2 ): 234 - 247 . DOI: 10.1016/S1470-2045(21)00692-6 http://doi.org/10.1016/S1470-2045(21)00692-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204521006926 https://linkinghub.elsevier.com/retrieve/pii/S1470204521006926

JANJIGIAN Y Y , SHITARA K , MOEHLER M , et al . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J ] . Lancet , 2021 , 398 ( 10294 ): 27 - 40 . DOI: 10.1016/S0140-6736(21)00797-2 http://doi.org/10.1016/S0140-6736(21)00797-2

SHITARA K , VAN CUTSEM E , BANG Y J , et al . Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1571 - 1580 . DOI: 10.1001/jamaoncol.2020.3370 http://doi.org/10.1001/jamaoncol.2020.3370 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922

HUANG J , MO H N , ZHANG W L , et al . Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China [J ] . Cancer , 2019 , 125 ( 5 ): 742 - 749 . DOI: 10.1002/cncr.31855 http://doi.org/10.1002/cncr.31855

XU J M , JIANG H P , PAN Y Y , et al . Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial [J ] . JAMA , 2023 , 330 ( 21 ): 2064 - 2074 . DOI: 10.1001/jama.2023.19918 http://doi.org/10.1001/jama.2023.19918

MURO K , VAN CUTSEM E , NARITA Y , et al . Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS [J ] . Ann Oncol , 2019 , 30 ( 1 ): 19 - 33 . DOI: S0923-7534(19)31003-8 http://doi.org/S0923-7534(19)31003-8

WANG F H , ZHANG X T , LI Y F , et al . The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021 [J ] . Cancer Commun , 2021 , 41 ( 8 ): 747 - 795 . DOI: 10.1002/cac2.v41.8 http://doi.org/10.1002/cac2.v41.8 https://onlinelibrary.wiley.com/toc/25233548/41/8 https://onlinelibrary.wiley.com/toc/25233548/41/8

MOEHLER M H , KATO K , ARKENAU H T , et al . Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) [J ] . 2023 , 41 ( 4_suppl ): 286.

HASEGAWA H , SHITARA K , TAKIGUCHI S , et al . A multicenter, open-label, single-arm phase Ⅰ trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer [J ] . Gastric Cancer , 2022 , 25 ( 3 ): 619 - 628 . DOI: 10.1007/s10120-022-01286-w http://doi.org/10.1007/s10120-022-01286-w

ANDRÉ T , TOUGERON D , PIESSEN G , et al . Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase Ⅱ study [J ] . J Clin Oncol , 2023 , 41 ( 2 ): 255 - 265 .

VERSCHOOR Y L , VAN DE HAAR J , VAN DEN BERG J G , et al . Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial [J ] . Nat Med , 2024 , 30 ( 2 ): 519 - 530 . DOI: 10.1038/s41591-023-02758-x http://doi.org/10.1038/s41591-023-02758-x

PIETRANTONIO F , RAIMONDI A , LONARDI S , et al . INFINITY: a multicentre, single-arm, multi-cohort, phase Ⅱ trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC) [J ] . J Clin Oncol , 2023 , 41 ( 4_suppl ): 358.

TERASHIMA M , IWASAKI Y , MIZUSAWA J , et al . Randomized phase Ⅲ trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501) [J ] . Gastric Cancer , 2019 , 22 ( 5 ): 1044 - 1052 . DOI: 10.1007/s10120-019-00941-z http://doi.org/10.1007/s10120-019-00941-z

CUNNINGHAM D , ALLUM W H , STENNING S P , et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J ] . N Engl J Med , 2006 , 355 ( 1 ): 11 - 20 . DOI: 10.1056/NEJMoa055531 http://doi.org/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531

YCHOU M , BOIGE V , PIGNON J P , et al . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial [J ] . J Clin Oncol , 2011 , 29 ( 13 ): 1715 - 1721 .

KANG Y K , YOOK J H , PARK Y K , et al . Phase Ⅲ randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY) [J ] . Ann Oncol , 2019 , 30 : v876 -v877.

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J ] . Lancet , 2019 , 393 ( 10184 ): 1948 - 1957 . DOI: 10.1016/S0140-6736(18)32557-1 http://doi.org/10.1016/S0140-6736(18)32557-1 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571

WANG X X , LI S , XIE T Y , et al . Early results of the randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE trial) [J ] . J Clin Oncol , 2020 , 38 ( 4_suppl ): 280.

YUAN S Q , NIE R C , JIN Y , et al . Author correction: perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial [J ] . Nat Med , 2024 , 30 ( 2 ): 605.

AL-BATRAN S E , LORENZEN S , THUSS-PATIENCE P C , et al . Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase Ⅱb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 4003.

SHITARA K , RHA S Y , WYRWICZ L S , et al . Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study [J ] . Lancet Oncol , 2024 , 25 ( 2 ): 212 - 224 . DOI: 10.1016/S1470-2045(23)00541-7 http://doi.org/10.1016/S1470-2045(23)00541-7

RHA S Y , OH D Y , YAÑEZ P , et al . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial [J ] . Lancet Oncol , 2023 , 24 ( 11 ): 1181 - 1195 . DOI: 10.1016/S1470-2045(23)00515-6 http://doi.org/10.1016/S1470-2045(23)00515-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156 https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156

ZHANG X , WANG J , WANG G , et al . LBA79 GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase Ⅲ study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma [J ] . Ann Oncol , 2023 , 34 : S1319 . DOI: 10.1016/j.annonc.2023.10.080 http://doi.org/10.1016/j.annonc.2023.10.080 https://linkinghub.elsevier.com/retrieve/pii/S0923753423042242 https://linkinghub.elsevier.com/retrieve/pii/S0923753423042242

JANJIGIAN Y Y , KAWAZOE A , YAÑEZ P , et al . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer [J ] . Nature , 2021 , 600 ( 7890 ): 727 - 730 . DOI: 10.1038/s41586-021-04161-3 http://doi.org/10.1038/s41586-021-04161-3

SATOH T , KANG Y K , CHAO Y E , et al . Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase Ⅲ clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer [J ] . Gastric Cancer , 2020 , 23 ( 1 ): 143 - 153 . DOI: 10.1007/s10120-019-00970-8 http://doi.org/10.1007/s10120-019-00970-8

JANJIGIAN Y Y , KAWAZOE A , BAI Y , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial [J ] . Lancet , 2023 , 402 ( 10418 ): 2197 - 2208 . DOI: 10.1016/S0140-6736(23)02033-0 http://doi.org/10.1016/S0140-6736(23)02033-0

LEE K W , BAI L Y , JUNG M , et al . 1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase Ⅰb/Ⅱ study [J ] . Ann Oncol , 2023 , 34 : S855 -S856.

ZHU L J , LI S , BAO J , et al . First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: a dose escalation and expansion phase Ⅰ study [J ] . J Clin Oncol , 2023 , 41 ( 4_suppl ): 356.

KAWAKAMI H , HIRONAKA S , ESAKI T , et al . An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability-high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7) [J ] . Cancers , 2021 , 13 ( 4 ): 805.

KIM S T , CRISTESCU R , BASS A J , et al . Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer [J ] . Nat Med , 2018 , 24 ( 9 ): 1449 - 1458 . DOI: 10.1038/s41591-018-0101-z http://doi.org/10.1038/s41591-018-0101-z

Views

2677

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Progress and prospects of gastric cancer treatment in the 21st century

Advanced progress in research and diagnosis of gastric cancer in 2022

Progress of important clinical trials of breast cancer in China in 2022

The current data and challenge of radiotherapy in the case management of gastric cancer

Related Author

Yuyang ZHANG

Qian LIU

Yonghu XU

Dazhi XU

Jinling JIANG

Chenfei ZHOU

Chao WANG

Liqin ZHAO

Related Institution

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Gastric Surgery, Division 1, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Department of Oncology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰